Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 163-170

  Hallett, William H D ^a   Ames, Erik ^a   Motarjemi, Milad ^a   Barao, Isabel ^a   Shanker, Anil ^b   Tamang, David L ^a   Sayers, Thomas J ^b   Hudig, Dorothy ^a   Murphy, William J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; FAS ANTIGEN; FAS LIGAND; HLA DR5 ANTIGEN; PERFORIN; PROTEASOME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; LEUKEMIA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; TUMOR CELL; TUMOR GROWTH; ANIMAL; CYTOTOXICITY; DRUG ANTAGONISM; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA; METABOLISM; MOUSE STRAIN; MULTIMODALITY CANCER THERAPY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA; MICE; MICE, INBRED STRAINS; NEOPLASMS; PERFORIN; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 40449100492     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.1.163     Document Type: Article

References (29)

1. Adams, J. 2002. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8: S49-S54.
2. Voorhees, P. M., and R. Z. Orlowski. 2006. The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol. 46: 189-213.
3. Ma, M. H., H. H. Yang, K. Parker, S. Manyak, J. M. Friedman, C. Altamirano, Z. Q. Wu, M. J. Borad, M. Frantzen, E. Roussos, et al. 2003. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9: 1136-1144.
4. Mateos, M. V., J. M. Hernandez, M. T. Hernandez, N. C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J. J. Lahuerta, J. de la Rubia, M. J. Terol, et al. 2006. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108: 2165-2172.
5. Goel, A., A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. A. Mesa, and S. J. Russell. 2005. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp. Hematol. 33: 784-795.
6. Sayers, T. J., A. D. Brooks, C. Y. Koh, W. Ma, N. Seki, A. Raziuddin, B. R. Blazar, X. Zhang, P. J. Elliott, and W. J. Murphy. 2003. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102: 303-310.
7. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187-376.
8. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
9. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211: 214-224.
10. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369: 31-37.
11. Hallett, W. H., and W. J. Murphy. 2006. Positive and negative regulation of natural killer cells: therapeutic implications. Semin. Cancer Biol. 16: 367-382.
12. Ortaldo, J. R., R. T. Winkler-Pickett, K. Nagashima, H. Yagita, and K. Okumura. 1992. Direct evidence for release of pore-forming protein during NK cellular lysis. J. Leukocyte Biol. 52: 483-488.
13. Sayers, T. J., A. D. Brooks, N. Seki, M. J. Smyth, H. Yagita, B. R. Blazar, and A. M. Malyguine. 2000. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J. Leukocyte Biol. 68: 81-86.
14. Woodard, S. L., S. A. Fraser, U. Winkler, D. S. Jackson, C. M. Kam, J. C. Powers, and D. Hudig. 1998. Purification and characterization of lymphocyte chymase I, a granzyme implicated in perforin-mediated lysis. J. Immunol. 160: 4988-4993.
15. Lundqvist, A., S. I. Abrams, D. S. Schrump, G. Alvarez, D. Suffredini, M. Berg, and R. Childs. 2006. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66: 7317-7325.
16. Verret, C. R., A. A. Firmenich, D. M. Kranz, and H. N. Eisen. 1987. Resistance of cytotoxic T lymphocytes to the lytic effects of their toxic granules. J. Exp. Med. 166: 1536-1547.
17. Harding, C. V., J. France, R. Song, J. M. Farah, S. Chatterjee, M. Iqbal, and R. Siman. 1995. Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway. J. Immunol. 155: 1767-1775.
18. Lowin, B., F. Beermann, A. Schmidt, and J. Tschopp. 1994. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 91: 11571-11575.
19. Richardson, P. G., C. Mitsiades, T. Hideshima, and K. C. Anderson. 2006. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57: 33-47.
20. Satou, Y., K. Nosaka, Y. Koya, J. I. Yasunaga, S. Toyokuni, and M. Matsuoka. 2004. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18: 1357-1363.
21. Sunwoo, J. B., Z. Chen, G. Dong, N. Yeh, C. Crowl Bancroft, E. Sausville, J. Adams, P. Elliott, and C. Van Waes. 2001. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7: 1419-1428.
22. Banning, U., H. Barthel, C. Mauz-Korholz, R. Kluge, D. Korholz, and O. Sabri. 2006. Effect of drug-induced cytotoxicity on glucose uptake in Hodgkin's lymphoma cells. Eur. J. Haematol. 77: 102-108.
23. Sutton, V. R., M. E. Wowk, M. Cancilla, and J. A. Trapani. 2003. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 18: 319-329.
24. Schumacher, L. Y., D. D. Vo, H. J. Garban, B. Comin-Anduix, S. K. Owens, V. B. Dissette, J. A. Glaspy, W. H. McBride, B. Bonavida, J. S. Economou, and A. Ribas. 2006. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J. Immunol. 176: 4757-4765.
25. Takeda, K., M. J. Smyth, E. Cretney, Y. Hayakawa, N. Yamaguchi, H. Yagita, and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-γ-dependent suppression of subcutaneous tumor growth. Cell. Immunol. 214: 194-200.
26. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161: 897-908.
27. Hoglund, P., C. Ohlen, E. Carbone, L. Franksson, H. G. Ljunggren, A. Latour, B. Koller, and K. Karre. 1991. Recognition of β 2-microglobulin-negative (β 2m-) T-cell blasts by natural killer cells from normal but not from β 2m- mice: nonresponsiveness controlled by β 2m- bone marrow in chimeric mice. Proc. Natl. Acad. Sci. USA 88: 10332-10336.
28. Dorfman, J. R., and D. H. Raulet. 1996. Major histocompatibility complex genes determine natural killer cell tolerance. Eur. J. Immunol. 26: 151-155.
29. Wallin, R. P., V. Screpanti, J. Michaelsson, A. Grandien, and H. G. Ljunggren. 2003. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur. J. Immunol. 33: 2727-2735.